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 Bisphosphonates (BPs) are one of the most common medications used in the treatment 
of osteoporosis.   Rare but serious conditions which have been associated with BP exposure 
include atrial fibrillation, esophageal cancer, atypical femoral fractures and osteonecrosis of the 
jaw.  There are many proposed risk factors for developing bisphosphonate related 
osteonecrosis of the jaw (BRONJ).   
 In the case study presented below, the patient is a 67 year old Caucasian female.  She 
has a history of breast cancer and is on Arimidex, an aromatase inhibitor (antiestrogen 
medication).  She is postmenopausal.  She has a history of a hip fracture and her DEXA scan 
indicates she has osteoporosis.  She is being placed on Fosimax which is an oral 
bisphosphonate.  A review of literature was conducted on bisphosphonate therapy and the 
development of BRONJ to see what additional considerations should be made for this patient. 
Background 
Osteoporosis is a bone condition “characterized by normal bone mineralization but low 
bone mass…and disruption of the bony architecture” (Dunphy, Winland-Brown, Porter & 
Thomas, 2015, p. 807).  Throughout life, bones continue to remodel and rebuild themselves.  
Osteoclasts break down bone while osteoblasts build new bone.  Typically osteoblasts and 
osteoclasts maintain a homeostatic relationship and bone turnover and rebuilding remain 
relatively stable.  This relationship is influenced by a number of hormones including estrogen.   
Estrogen “has been shown to inhibit osteoclastogenesis, induce osteoclast apoptosis, and 
decrease erosive activity of osteoclasts” (Dunphy et al., 2015, p. 810).  Therefore 
postmenopausal women (or women being treated with antiestrogen medications) are at an 
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increased risk of developing osteoporosis due to osteoclastic activity outpacing osteoblastic 
activity.   
 Osteoporosis is treated through a variety of lifestyle management treatments, 
nutritional supplementation of calcium and Vitamin D, and various medications including 
bisphosphonates therapy.   
Bisphosphonate Therapy 
Bisphosphonate (BP) therapy is the most common pharmacological intervention in the 
treatment of osteoporosis.  Bisphosphonates reduce the activity of osteoclasts which decreases 
the rate of bone resorption and increases the bone density.  BPs bind tightly to the surface of 
bones.  Absorption of oral BPs are around 1% while absorption of IV BPs are higher than 50%.  
Bisphosphonates levels decrease rapidly in plasma but may last as long as 10 years in bone 
structures (Hasegawa et al., 2013; Sigua-Rodriguez, Da Costa Riberiro, De Brito, Alvarez-Pinzon, 
& De Albergaria-Barbosa, 2014). 
Oral bisphosphonates are typically well tolerated but do require specific patient 
education on administration and potential side effects.  Most oral bisphosphonates are 
available in daily or weekly formulations.  They must be taken on an empty stomach with at 
least 8 ounces of water to maximize absorption and decrease the risk of the medication sticking 
in the esophagus.  The patient must remain in an upright position for a minimum of 30 minutes 
after taking the medication to decrease complications of reflux.  Oral BPs are contraindicated in 
those with esophageal disorders, a history of certain bariatric surgeries, and those unable to 
remain upright for 30 minutes following medication administration (Rosen, 2017).   
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IV BPs side effects include an increase the risk of hypocalcemia and transient flu-like 
symptoms (Rosen, 2017).  IV BPs are most commonly used at much higher doses than oral BPs 
to treat metastatic cancers (especially breast, lung, and prostate) and multiple myeloma.  
Rare but serious conditions which have been associated with BP exposure include atrial 
fibrillation, esophageal cancer, atypical femoral fractures and osteonecrosis of the jaw (Suresh, 
Pazianas & Abrahamsen, 2014).  This paper will focus on bisphosphonate related osteonecrosis 
of the jaw (BRONJ). 
Case Report 
Date:  3/10/2017 
 
Chief Complaint:  8 week post-op recheck for right hip replacement 
 
Subjective 
HPI:  The patient is a 67 year old Caucasian female who presents today for post-hospitalization 
follow-up.  Eight weeks ago she fell in the bathtub, developing a right hip fracture which 
required total right hip replacement.  She reports her incision is healing well.  She denies any 
redness or signs of infection.  She had not had any fevers.  She has completed physical therapy 
and is able to ambulate without difficulty.  She feels she has healed well and has good range of 
motion in her hip.  Takes 650 mg Tylenol TID for pain which she rates at an average of 3/10 
(worst).  With medication, her pain is 0/10.  Denies any other physical complaints or concerns 
at this time. 
 
Past medical history: hypertension, right breast cancer 
 
Surgeries: right hip replacement (2017), right breast lumpectomy 
 
Medications: Lisinopril 10 mg PO daily, Arimidex 1 mg PO daily, Tylenol 650 mg PO TID PRN.  
Denies supplements, herbs, homeopathic treatments or other OTC medications. 
 
Allergies:  NKDA.  No food, environmental or latex allergies. 
 
Social history:  She is a retired high school Chemistry teacher.  She is widowed and has three 
grown children.  She is a current smoker of ½-1 pack of cigarettes daily with a 75 year pack 
history.  Drinks 1-2 alcoholic drinks per month.  No current exercise plan but has been walking 
daily since her hip replacement.  Denies any illegal drug use. 
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Family history:  Non-contributory.   
 
Screenings/preventive care: 
Mammogram – last completed October 2016, negative 
Pap smear – unsure when she last had one completed.  Reports she has never had abnormal 
screen. 
Colonoscopy – has not had one 
Dexa scan – 5/16/2011 
Lung cancer screening – has not had one 
Hepatitis C screening – has not had one 
Dentist – sees regularly 
Eye exam – not addressed 
 
Immunizations: 
TD/Tdap – unsure of last date 
Influenza – none this season 
Pneumovax – has not received 
Zostavax – had recently, unsure of date 
 
ROS 
Constitutional:  Denies fever, chills, night sweats.  No recent weight loss. 
Chest:  No chest pain or palpitations.  No shortness of breath.  No cough or cold symptoms. 
GI/GU:  No changes in appetite.  No changes in bowel or bladder habits.  No dark or tarry stools.  
No blood in urine.  No urgency or frequency. 
MSK:  See HPI.   
Mental health:  Reports her mood has been good. 
 
Objective 
Vital signs:  see chart 
 
Physical exam 
General:  Patient is well-groomed.  No distress.  Answers questions thoroughly. Maintains 
bright affect and good eye contact.  Cooperative throughout examination. 
Lungs:  Breathing easy, regular and unlabored.  Breath sounds clear through all lung fields, no 
wheezes or crackles. 
Heart:  Regular heart rate and rhythm.  S1, S2, no murmur. 
Abdomen:  Soft, nontender, no organmegaly.   
Right hip:  Incision healed.  No unusual erythema or swelling.  No signs of infection.  No 
tenderness to palpation.  Appropriate range of motion.  
 
DEXA scan 
Lumbar spine: The total BMD for L1 to L4 is 0.594 g/cm.  The BMD is 67% of the young adult 
reference population and 69% of the age matched population.  The T-score is -4.1. 
 WHO classification – osteoporosis 




Femoral neck:  The total BMD is 0.620 g/cm.  The BMD is 73% of the young adult reference 
population and 90% of the age matched population.  The T-score is -2.1. 
 Who classification – osteopenia  
 
Comparison: Today’s study is compared with a previous examination dated 5/16/11 and a 
baseline examination of 5/18/2010.   
 
Lumbar spine:  There has been an interval decrease in lumbar spine BMP of 1.7% when 
compared to the baseline examination with an interval increase of 2.9% when compared to the 
previous examination. 
 
Hip:  There has been an interval increase in hip BMP of 0.2% when compared to the baseline 
examination with an interval decrease of 1.0% when compared to the previous examination. 
 
Conclusion: 
1. Bone density consistent with osteoporosis. 
2. Fracture risk is high.  
 
Recommendations: 
1.  Adequate vitamin D and calcium. 
2. Follow up DEXA scan in 2 years to evaluate for change or response to treatment. 
 
Assessment 
1.  8 week right hip replacement post-operative exam 
2.  Osteoporosis 
 
Plan 
Patient presents today for post-op exam following a right hip replacement secondary to falling 
in her bathtub and fracturing hip 8 weeks ago.  She has successfully completed physical therapy 
and has good ROM in her hip.  I have encouraged her to continue walking daily.  As she feels 
her pain is at a manageable level, I have encouraged her to decrease the amount of Tylenol she 
is taking daily and discontinue it if possible.  She should follow-up with orthopedics as 
scheduled. 
 
DEXA scan completed today shows findings consistent with osteoporosis and her BMD has 
decreased from baseline and last DEXA scan.  Patient will begin vitamin D and calcium 
supplements daily.  Fosimax 70 mg PO weekly prescribed.  Instructions regarding medication 
provided.  Patient is to call my office if she has any problems tolerating this medication. 
 
Provided counseling on tobacco cessation.  Patient is not interested in quitting smoking at this 
time. 
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Recommended patient schedule well-visit to review needed screenings and general health.  
Influenza and Pneumovax will be given today.   
 
Patient in agreement with the above treatment plan.  Denies any questions at this time.  She 




 In the case study presented, the patient is a 67 year old Caucasian female.  She has a 
history of breast cancer and is on Arimidex, an aromatase inhibitor (antiestrogen medication).  
She is postmenopausal.  She has a history of a hip fracture and her DEXA scan indicates she has 
osteoporosis.  She is being placed on Fosimax which is an oral bisphosphonate.  A review of 
literature was conducted on oral bisphosphonate therapy and the development of BRONJ to 
see what additional considerations should be made for this patient. 
Pathophysiology and Diagnosis of BRONJ 
 While the exact pathophysiology of BRONJ is not fully understood, there are two 
proposed theories. 
One is the osteoclast-based, “inside-out,” theory, in which inhibition of osteoclastic 
activity and marked suppression of bone turnover, together with spread of physiologic 
micro-damage and possibly local infection, leads to bone death within the jaw, with 
subsequent exposure.  As such, the bone exposure is a late event.  The second, “outside-
in,” theory suggests a break in the oral mucosa leads to ingress of bacteria and local 
infection which, coupled with poor bone remodeling, leads to bone death (Lerman et 
al., 2013, p. 977). 
OSCE CASE STUDY  9   
 
 
Additionally, it is believed that BPs may destroy some of the microvasculature of bone, 
causing decreased wound healing (Hasegawa et al., 2013) and there is a reduction of 
endothelial derived growth factors (Vaszilko et al., 2014). 
The American Society for Bone Mineral Research has developed three criteria for the 
diagnosis of BRONJ: “(1) current or previous treatment with bisphosphonate; (2) exposed bone 
in the maxillofacial region that has persisted for more than eight weeks; and (3) no history of 
radiation therapy to the jaws” (Coskun Benlidayi & Guzel, 2013, p. 1).  The American 
Association of Oral and Maxillofacial Surgeons (AAOMS) list several risk factors for developing 
BRONJ including: drug related risk-factors, duration of therapy, local risk factors, demographic 
and systemic risk factors, genetic risk factors, and preventative factors (Coskun Benlidayi & 
Guzel, 2013). 
Drug Related Risk Factors 
Shintani et al. (2015) conducted a study of 59 patients who were treated for BRONJ in 
Japan.  The aim of their study was to compare the prognosis of patients who received oral BPs 
with those treated with IV BPs.  All patients discontinued BP therapy when they were diagnosed 
with BRONJ.  The treatment of BRONJ lesions was based on the severity of the lesion and 
followed the guidelines defined by AAOMS.   
There were 29 patients in the oral BP group and 30 patients in the IV BP group (although 
3 were eventually excluded as they refused treatment for BRONJ).  In the oral BP group, 28 of 
the patients were being treated for osteoporosis and one for Paget ’s disease.  The patients in 
the IV BP group were being treated for malignancies including 18 for breast cancer, 6 for 
multiple myeloma, 4 for prostate cancer, and 1 each for gastric cancer and hepatocellular 
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carcinoma.  Each patient was seen monthly for a year after diagnosis and treatment of their 
BRONJ lesion.   
In the oral BP group, 27 of 29 patents (93%) were fully healed within the year while only 
12 of 27 patients (44%) who received IV BPs were fully healed.  This indicates that patients who 
are on oral BP therapy and develop BRONJ may recover quicker than those who have been 
treated with IV BPs. 
Duration of Therapy  
Barasch et al. (2011) compared 191 patients with osteonecrosis of the jaw (ONJ) with 
573 matched control patients (3 for each ONJ patient).  Their patients stemmed from 3 areas in 
the United States.  All forms of ONJ were included although patients with a history of facial 
trauma or sickle cell disease were excluded.  Data collected included “tooth loss, periodontal 
disease, caries, endodontic problems, gingival bleeding, suppuration, pain or sensitivity, 
neurosensory disturbances, and information on dental procedures” (p. 440) which occurred in 
the 3 years preceding diagnosis of ONJ (or the previous 3 years for the case controlled 
matches). 
The researchers found that 113 of 191 (83%) of the ONJ patients and 71 of 573 (15%) of 
the control patient had been on BP therapy.  Median length of use was 5.6 years for the ONJ 
patients and 4.2 years for the control cases.  “Duration of bisphosphonate use < 2 years was 
associated with a ten-fold risk of ONJ, while with duration > 2 years, that risk nearly 
quadrupled” (Barasch et al., 2011, p. 441).  Additionally, the risk of developing ONJ was higher 
in patients treated with IV BPs as compared to oral BPs. 
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Local Risk Factors  
Pichardo and van Merkesteyn (2013) conducted a study reviewing 45 patients in the 
Netherlands diagnosed with BRONJ to determine if a dental origin could be found.  Sixteen 
patients had received oral BP therapy for a minimum of 24 months each.  Twenty-nine patients 
had received IV BP therapy for a minimum of 12 months each.  The patients were classified into 
4 groups based on the cause of their BRONJ lesion: a certain dental focus (recent dental 
procedure or pre-existence of periodontal disease at site of lesion), a presumable dental focus 
(an elevated mylohyoid ridge or trauma caused by ill-fitting dentures), spontaneous (with no 
previous dental history or trauma) and unknown (unclear or untraceable dental history). 
In 36 of the 45 cases a certain dental focus was found.  In 9 of the 45 cases a presumable 
dental focus was found.  There were no cases of spontaneous BRONJ.  One of the 45 cases was 
of unknown origin.  They did not find a difference in the origin of BRONJ lesions in those taking 
oral BPs compared to those taking IV BPs. 
Dental extraction. 
Dental extraction has been proposed as a major risk factor of developing ONJ.  Following 
a tooth extraction, patients have a 5.3 to 53 times higher risk of developing ONJ.  However, oral 
bacterial infections (such as those stemming from an infected tooth) may also place a patient 
on BPs at high risk of developing BRONJ, so extraction of an infected tooth may not be 
avoidable (Yamazaki et al., 2012). 
 Yamazaki et al. (2012) conducted a cohort study to “estimate the cumulative incidence 
(of developing ONJ) after tooth extraction in patients with and without administration of BP, 
and to identify potential risk factors, including oral status” (p. 1398).  They conducted a 
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retrospective analysis of 3,216 patients who had tooth extraction surgery at a university 
hospital in Japan.  Patient information collected included patient demographics, risk factors, 
types of BPs administered, and the condition of dental status.   
 There were 126 patients who had been treated with BPs (86 received oral BPs, 17 
received IV BPs).  There were 3,090 patients who had no history of BP therapy.  Of the 126 
patients with a history of BP therapy, 5 (3.9%) developed BRONJ.  Only 1 (0.032%) of the 3,090 
patients who were BP naïve developed ONJ. “By route of administration, cumulative incidence 
was 1.0% among patients treated with oral BP and 14.8% in those treated with intravenous BP 
(Yamazaki et al., 2012, p. 1400).   
 The authors found the major risk factor of ONJ development was BP therapy, especially 
when given intravenously.  Age alone was not a significant risk factor; however patients over 
the age of 65 had a higher rate of IV BP treatment, therefore increasing their risk.  Smoking 
status, steroid use, chemotherapy, diabetes, and oral health were not statistically significant 
risk factors in this study.  Poor oral health had been found to be a risk factor in other studies, 
but the authors of this study report their patients received oral examinations, screenings, and 
oral cleaning which may have decreased the potential complications of poor oral health among 
their participants. 
 Due to the low number of patients who developed ONJ, the authors report it is difficult 
to conclusively determine which additional risk factors may lead to developing ONJ lesions.   
Dental implants. 
 Dental implants have also been suggested as a risk factor for developing BRONJ.  López-
Cedrún et al. (2013) conducted a retrospective study of 9 patients who were treated with oral 
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BPs, received dental implants, and developed BRONJ within 3 years.  The participants of this 
study lived within a 100 kilometer radius of Galicia, Spain.  The aim of their study was “to 
describe the clinical characteristics of BRONJ associated with dental implants in patients taking 
bisphosphonates orally” (López-Cedrún et al., 2013, p. 875). The data variables collected 
included:  
sex, age, type of bisphosphonate given, indications for and duration of treatment, 
coexisting conditions, use of corticosteroids, smoking, number and sites of implants 
inserted, number of implants involved in the BRONJ lesion, interval between the 
insertion of the implant and the development of BRONJ, clinical presentation of the 
lesions, treatment of the lesions, and the clinical course (López-Cedrún et al., 2013, p. 
875). 
Their study involved 9 patients (8 women, 1 man) who received a total of 57 dental 
implants (29 mandibular and 28 maxillary).  BRONJ lesions were more commonly found 
involving the mandibular implants (present in 8 of the 9 patients), especially in the molar and 
premolar areas.  Four of the patients developed BRONJ within the first year of receiving dental 
implants; the other 5 patients developed BRONJ later than one year. 
Due to the limited number of patients in this study, the researchers were unable to 
determine which coexisting factors may influence the development of BRONJ.   
Demographic and Systemic Risk Factors  
 Osteoporosis. 
Huang et al. (2015) conducted a population-based cohort study in Taiwan containing 
two groups who received dental extractions between the years 2000 and 2010.  The first group 
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contained 19,399 patients who were diagnosed with osteoporosis.  The second group 
contained 38,669 age and gender matched comparison patients.  Patients with a history of 
osteonecrosis were excluded from both groups.  The goals of this study are “(1) to investigate 
the incidence of BRONJ in osteoporotic patients with oral BPs administration, and (2) to 
estimate the correlation between BRONJ and BPs usage in patients with osteoporosis” (Huang 
et al., 2015, p. 3).  
 After controlling for age, gender, hypertension, diabetes and cancer; the researchers 
found the osteoporosis group developed ONJ at a rate of 11.72 per 10,000 person-years 
compared to 5.32 per 10,000 person-years in the non-osteoporosis group.  The rate of ONJ 
development slightly increased (but not statistically significant) in patients who were treated 
with oral BPs and those with mild osteoporosis who did not receive BP treatment as compared 
to those without osteoporosis.  However, those who had a large cumulative dose of BPs or had 
used BPs for many years had a statistically higher rate of developing ONJ than patients without 
osteoporosis.   
In both cohorts, when the annual frequency of dental extraction increased, the risks of 
developing ONJ increased.  Both groups had low rates of ONJ with an annual frequency of 
dental extraction below two.  However, patients who had osteoporosis treated with BPs who 
had more than two dental extractions in one year developed ONJ at a rate of 46.6 per 10,000 
person-years.  Frequent dental extractions may be related to poor dental hygiene and dental 
care which may independently raise the risk of ONJ development.  Based on their research and 
review of literature, the researchers reported that the severity of osteoporosis is a large factor 
in the development of ONJ while BPs “play a synergistic role” (Huang et al., 2015, p. 9).   




 Vaszilko et al. (2014) conducted a prospective study involving 93 patients (74 females, 
19 males) seen at their clinic in Budapest who were diagnosed with BRONJ.  Comorbid diseases 
were recorded.  Each patient’s ONJ lesion was surgically treated in a similar manner and 
recurrence rates were noted.  As it is well known that lower levels of estrogen increase 
osteoporosis risks, the authors wanted to explore if there is a relationship between 
antiestrogen therapy and BRONJ development.   
 Thirty-seven of the 93 patients in this study had breast cancer with 80% of those 
patients having estrogen receptor positive cancer treated with antiestrogen therapy.  The 
researchers found that patients who had estrogen receptor negative breast cancer developed 
recurrent BRONJ at rates similar to other underlying pathologies (such as multiple myeloma or 
prostate cancer).  However, patients with estrogen positive cancer treated with antiestrogen 
therapy developed recurrent BRONJ lesions at a statistically significant higher rate than breast 
cancer patients who were not on antiestrogen therapy.  This indicates that breast cancer itself 
is not a risk factor but rather decreased estrogen levels that may lead to recurrent BRONJ 
lesions. 
Oral health in postmenopausal women. 
Grgić et al. (2017) conducted a non-interventional clinic study of 120 postmenopausal 
women treated at a single dental clinic in Serbia.  The women were 50 to 70 years old and 
postmenopausal.  They were divided into three groups.  The first group (O) consisted of 45 
women diagnoses with osteoporosis and had never been on BP therapy or had been treated 
with oral BPs for less than 6 months.  The second group (OBP) consisted of 45 women 
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diagnosed with osteoporosis who had been on oral BP therapy for 6 months or more.  The 
third, control group (C) consisted of 30 women who did not have osteoporosis.  Each patient 
was examined by the same periodontist and periodontal health was measured using the plaque 
index, the gingival index, the bleeding index, clinical attachment loss, pocket depth, and the 
DMFT (decayed, missing, and filled teeth) index. 
“Our study showed that women who are taking BP therapy had higher gingival index 
than C or O group and higher pocket depth than the O group” (Grgić et al., 2017, p. 155).  The 
OBP group also had an increased bleeding index.  However, they did not find significant 
differences in the overall stage of periodontal disease between the three groups.  The 
researchers concluded that oral BP therapy may cause local irritation in the oral cavity, leading 
to increased risk of lesion development. 
Preventative Factors 
There is much debate regarding how BRONJ lesions should be treated.  “Specific 
management regimens have included chlorhexidine rinses, antibiotic therapy, non-surgical 
sequestrectomy, and surgical debridement and/or resection of necrotic bone (Lerman et al, 
2013, p. 978).  Most organizations recommend conservative management however these 
guidelines are based on expert opinion and have not been thoroughly researched.   
Two surgical interventions. 
 Mozzati, Arata, and Gallesio (2013) completed a prospective study comparing two 
different surgical tooth extraction procedures on patients who were receiving oral BP therapy 
at a single dental center in Italy.  All of the patients were currently on BP therapy, had been 
taking oral BPs for a minimum of 24 months and had never had irradiation of the maxillofacial 
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area or previous dental extractions.  “A total of 334 subjects were treated with delicate surgery 
and closure by primary intention (Protocol A), while the other 366 were treated with 
nontraumatic avulsion and closure by secondary intention (Protocol B)” (p. 1708).  All patients 
received a radiologic examination preoperatively and one year postoperatively.  They also 
received professional oral hygiene one week prior to surgery.   
 There were a total of 700 patients between the two groups and a total of 1,480 
extractions completed.  None of the patients developed BRONJ or experienced delayed healing.  
Based on their results and review of literature, the researchers proposed that BRONJ 
development in patients on oral bisphosphonate therapy is a rare complication but good oral 
care and minimally traumatic oral surgery may further reduce the risk. 
Discontinuing BP therapy prior to dental surgery.  
Hasegawa et al. (2013) completed an observational study to determine how 
discontinuing oral BP therapy for 3 months prior to tooth extraction affects the development of 
BRONJ and wound healing.  Their study included 212 Japanese patients (18 males and 183 
females), with a total of 434 teeth extracted.  The first group (101 patients, 262 teeth) 
discontinued BP treatment for 3 months prior to having their extraction surgery.  The second 
group (111 patients, 172 teeth) continued on BP treatment as it was deemed too risky for them 
to discontinue their BP medication or the oral surgery was required sooner than 3 months. 
 There were no cases of BRONJ development in the group that discontinued BPs prior to 
surgery although there were 2 cases which had delayed wound healing following tooth 
extraction.  They were treated with antibiotics and a mouth rinse.  Both cases healed within 12 
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weeks.  One case of BRONJ developed in the second group, developing an intraoral fistula with 
bone exposure.  At 120 weeks after tooth extraction, this wound was not yet fully healed. 
Based on the results on their study and their review of literature, the authors suggested 
discontinuing oral BPs 3 months prior to and 3 months after elective invasive dental surgery 
when possible.  As BPs remain in bone for several years after discontinuation, they conclude:  
Discontinuation of BP therapy for a few months may have little effect on the BP that has 
already incorporated into the bone.  However, other effects of BP, such as its 
antiangiogenic activity and inhibition of proliferation and migration of epithelial cells, 
may be reduced, and this may help healing of the overlying mucosa (Hasegawa et al.,  
2013, p. 561). 
Learning Points 
 While the body of knowledge regarding BRONJ lesions is vast, consensus regarding the 
development, risk factors, and treatment of BRONJ is not fully understood and the available 
evidence is contradictory at times.  Regarding the studies collected in this review of literature, 
several weaknesses are present.  Most of the studies enrolled patients in limited geographical 
area.  Some of the studies contained too few patients to make generalized assumptions 
regarding BRONJ.  Each of the studies by itself does not provide evidence that is strong enough 
to apply to a generalized population but each study adds to the growing body of knowledge 
that makes understanding of this condition stronger. 
 The patient in the case study has several risk factors of developing BRONJ.  She has 
osteoporosis which has been found to be an independent risk factor (Huang et al., 2015).  As 
she is starting on oral BP therapy, she needs to be aware that this does increase her risk of 
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developing BRONJ but the risk is very small compared to IV therapy (Shintani et al., 2015; 
Barasch et al., 2011; Yamazaki et al., 2012).  The risk does increase the longer she is on the 
medication, with nearly a 4-fold increase after being treated with BPs for longer than 2 years 
(Barasch et al., 2011).  An expert panel has suggested moderate-risk patients be placed on a 
drug holiday after 5 years of BP treatment (Suresh et al., 2013).  
 The majority of BRONJ lesions are of known dental origin (Pichardo and van Merkesteyn, 
2013).  Dental extraction and/or dental implants may be a triggering event for the development 
of BRONJ (Yamazaki et al., 2012; López-Cedrún et al. 2013).  Additionally, oral BPs may cause 
local irritation in the mouth which may precipitate BRONJ development (Grgić et al., 2017). 
 This patient has a history of breast cancer that was estrogen receptor positive.  She is on 
an antiestrogen medication.  Use of this medication can increase the severity of her 
osteoporosis and may be an additional risk factor for developing BRONJ (Vaszilko et al., 2014). 
 This patient should receive regular oral care and cleanings.  She should be aware that 
she should see a dentist if she develops any oral pain or lesions.  If she requires oral surgery, it 
is important her provider is aware that she is on oral BP therapy.  The provider should consider 
discontinuing her BP medication for up to 3 months before and after the surgery if delaying the 
surgery will not compromise the patient (Hasegawa et al., 2013).   
 While the use of oral bisphosphonate therapy does carry a risk, the benefits of the 
medication make it an appropriate choice for the patient in the case study.  After educating the 
patient on the benefits and risks of the medication, if she is in agreement with starting the 
medication, the provider should prescribe it immediately.  She should be educated on 
appropriate dental care and what to do if she develops oral pain or lesions.  At each follow-up 
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visit, the provider should discuss this medication with the patient to determine if she is 
compliant with taking the medication as prescribed and if she is experiencing any side effects.  
The provider and patient should collaborate on the plan of care on a yearly basis and determine 
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